A phase II study of bryostatin 1 in metastatic malignant melanoma.

por Propper, D. J., Macaulay, V., O'Byrne, K. J., Braybrooke, J. P., Wilner, S. M., Ganesan, T. S., Talbot, D. C., Harris, A. L.
Publicado 1998

Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents

por Han, C, Braybrooke, J P, Deplanque, G, Taylor, M, Mackintosh, D, Kaur, K, Samouri, K, Ganesan, T S, Harris, A L, Talbot, D C
Publicado 2003

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbaz...

por Propper, D J, Braybrooke, J P, Levitt, N C, O'Byrne, K, Christodoulos, K, Han, C, Talbot, D C, Ganesan, T S, Harris, A L
Publicado 2000

Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer

por Levitt, N C, Propper, D J, Madhusudan, S, Braybrooke, J P, Echeta, C, te Poele, R, Davies, S L, Flanagan, E, Hickson, I D, Joel, S, Ganesan, T S
Publicado 2005

Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer

por O'Byrne, K J, Dobbs, N, Propper, D J, Braybrooke, J P, Koukourakis, M I, Mitchell, K, Woodhull, J, Talbot, D C, Schally, A V, Harris, A L
Publicado 1999

Expert UK consensus on the definition of high risk of recurrence in HER2-negative early breast cancer: A modified Delphi panel

por Copson, E.R., Abraham, J.E., Braybrooke, J.P., Cameron, D., McIntosh, S.A., Michie, C.O., Okines, A.F.C., Palmieri, C., Raja, F., Roylance, R., Spensley, S.
Publicado 2023

Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer

por Propper, D J, Levitt, N C, O'Byrne, K, Braybrooke, J P, Talbot, D C, Ganesan, T S, Thompson, C H, Rajagopalan, B, Littlewood, T J, Dixon, R M, Harris, A L
Publicado 2000

Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha

por Braybrooke, J P, Propper, D J, O’Byrne, K J, Koukourakis, M I, Patterson, A V, Houlbrook, S, Love, S D, Varcoe, S, Taylor, M, Ganesan, T S, Talbot, D C, Harris, A L
Publicado 2000

The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication

por Hooper, C E, Lyburn, I D, Searle, J, Darby, M, Hall, T, Hall, D, Morley, A, White, P, Rahman, N M, De Winton, E, Clive, A, Masani, V, Arnold, D T, Dangoor, A, Guglani, S, Jankowska, P, Lowndes, S A, Harvey, J E, Braybrooke, J P, Maskell, N A
Publicado 2015

The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial

por Arnold, D T, Hooper, C E, Morley, A, White, P, Lyburn, I D, Searle, J, Darby, M, Hall, T, Hall, D, Rahman, N M, De Winton, E, Clive, A, Masani, V, Dangoor, A, Guglani, S, Jankowska, P, Lowndes, S A, Harvey, J E, Braybrooke, J P, Maskell, N A
Publicado 2015